Scientists in Finland have developed a nanodevice that can measure the absolute power of microwave radiation down to the femtowatt level at ultra-low temperatures — a scale trillion times lower than routinely used in verifiable power measurements. The device has the potential to significantly advance microwave measurements in quantum technology. Read...
Read MoreCarrar, a leading innovator in thermal management solutions for electric vehicles (EVs), and Gentherm, a global pioneer in thermal management and pneumatic comfort technologies for the automotive industry, have come together to revolutionize the EV sector. Their partnership aims to deliver EV battery modules leveraging a two-phase immersion thermal management solution that ensures absolute control of liquid level, vapor, and pressure at all times. Read more...
Read MoreTEL AVIV, Israel, May 25, 2023 /PRNewswire/ — A report published today by Perception Point, a leading provider of advanced threat prevention across digital channels, has identified a 356% growth in the amount of advanced phishing attacks attempted by threat actors in 2022. Overall, the total number of attacks increased by 87%, highlighting the growing threat that cyber attacks now pose to organizations. Perception Point’s ‘2023 Annual Report: Cybersecurity Trends & Insights’ examines cyber threats based on intelligence gathered from the company’s Advanced Threat Prevention solutions, which intercept attacks across email, web browsers, and cloud collaboration apps. Read...
Read MoreMOUNT KISCO, N.Y., May 25, 2023 /PRNewswire/ — Dandelion Energy, the nation’s leading home geothermal company, urges the New York Senate to pass S6604 as soon as possible, following the bipartisan approval in the Senate Committee on Environmental Conservation earlier this week and passage of companion legislation A6949 by the full New York Assembly last week. Read...
Read MoreLARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today shared interim results from an ongoing Phase 1/2 trial of AU-007, as detailed in the online publication of Abstract e14507 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Read...
Read More
